


Pharmacist Clinical Tool for Initiating Shingrix Discussions

Shingrix is the first non-live adjuvanted recombinant zoster vaccine (RZV) to help protect adults 50 years of age or older against shingles.



Abbreviations

HZ: herpes zoster; **LZV:** live zoster vaccine; **NACI:** National Advisory Committee on Immunization; **NIHB:** Non-Insured Health Benefits Program; **OHIP:** Ontario Health Insurance Plan; **PHN:** postherpetic neuralgia; **RZV:** recombinant zoster vaccine; **VAC:** Veteran Affairs Canada

DISCLAIMER:

This tool was developed by the Ontario Pharmacists Association (OPA) with a grant provided by GlaxoSmithKline Canada (GSK). The information provided in this document is intended to assist pharmacists with initiating discussions with patients about RZV but does not replace professional judgement and responsibilities. It is intended to supplement materials provided by regulatory authority, and should there be any discrepancies, municipal, provincial, and federal laws, policies and guidelines shall prevail. The information provided in this document are current at the time of publication. The decision for use and application of this document is the responsibility of the user. OPA assumes no liability for such use and application or any resulting outcomes.

REFERENCES:

- Canadian Immunization Guide. Herpes zoster (shingles) vaccine. Last updated Feb 13, 2020. Accessed Sept. 6, 2021 <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-shingles-vaccine.html>
- Evans, GA. Herpesvirus Infections. Therapeutic Choices. Canadian Pharmacists Association. Last updated Apr. 14, 2021. Accessed Sept. 6, 2021 <http://www.myrx.ca>
- GlaxoSmithKline. Shingrix: The First Non-Live Adjuvanted Vaccine to Help Protect Against Shingles. Accessed Sept. 7, 2021 https://ca.gsk.com/media/1598992/13419_gsh_dtc_factsheet_en_05_clean_final_2019.pdf
- GlaxoSmithKline. Shingrix Product Monograph. Last updated June 3, 2020. Accessed Sept. 7, 2021 https://ca.gsk.com/media/1350788/shingrix_pm-2017-10-13.pdf
- National Advisory Committee on Immunization. Updated Recommendations on the Use of Herpes Zoster Vaccines. Last updated Aug. 30, 2018. Accessed Sept. 7, 2021 <https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html>
- GlaxoSmithKline. Shingrix Efficacy Data. Accessed Sept. 7, 2021 <https://shingrixhcp.com/efficacy-safety/efficacy-data/>
- GlaxoSmithKline. Shingrix Patient Brochure. Last updated Sept. 2018. Accessed Sept. 7, 2021 https://gskpro.com/content/dam/global/hcpportal/en_CA/products/Shingrix/GlaxoSmithKline%20Patient%20Brochure.pdf
- Ontario Ministry of Health. Ontario Publicly Funded Shingles (Herpes Zoster) Immunization Program. Shingrix® Vaccine Information for Patients. Accessed Sept. 7, 2021 https://www.health.gov.on.ca/en/public/programs/immunization/docs/shingles_patient_fact_sheet_en.pdf